

# Entreprise de Fabrication Pharmaceutique de 40 Ans





**MERGERSCORP**

The Leader In Business Sales Mergers & Acquisitions

## Entreprise de Fabrication Pharmaceutique de 40 Ans

La société a été fondée dans le district du Pendjab en Inde en 1982 dans le but de fabriquer des ingrédients pharmaceutiques actifs.

La société est une société de fabrication d'ingrédients pharmaceutiques actifs (API) qui fabrique les matières premières pour plusieurs grandes entreprises de l'industrie pharmaceutique, qui utilisent ces produits pour fabriquer des médicaments.

Ils fournissent des produits à des entreprises telles que Pfizer, Abbott, Cipla, Glenmark, Macleods, Aristo, etc.

Les offres de la société vont des antibiotiques, des vitamines, des anticoagulants aux produits ophtalmiques. Les entreprises sont également auditées par plusieurs organisations telles que ISO, ZED et GMP par des organismes de réglementation en Inde et à l'étranger.

### Recherche

L'entreprise travaille sur une technologie brevetée pour une protéine recombinante qui fonctionne sur une nouvelle thérapie ciblée et assure également l'absence d'effets secondaires. Actuellement, les opérations se concentrent sur de nouvelles molécules haut de gamme.

### Étude

La société mène actuellement des études expérimentales sur les thérapies de rajeunissement des cellules souches qui promettent également un avenir de médicaments sans effets secondaires.

### Biotechnologie

La société est engagée dans d'importantes activités de recherche en biotechnologie dans le domaine des protéines thérapeutiques humaines ciblées. Ses travaux de recherche actuels se concentrent sur la création d'un nouveau médicament qui, tout en guérissant les patients asthmatiques et allergiques, peut également agir sur la mastocytose et la leucémie basophile.

### Equipe

L'équipe est composée de 100 personnes éclairées, Chimistes, Pharmaciens, Biotechnologues, Contrôleurs de qualité, experts en R & D, Personnel d'entreposage.

Marché: 65% Inde / 35% Reste du monde / Europe

Produits: 25 Produits OEM / Ingrédients Actifs Pharmaceutiques Matière première

Le Plus Vendu: Antibiotiques

Normes: ISO9001, normes de l'UE (pas de FDA)

Taux de croissance: 20%+ / An

Taille: Plus de 100 employés

Gestion: Formation d'Ingénieur chimiste

Financier: Chiffre d'affaires de 25 millions de dollars / BAIIA de 3 MILLIONS de dollars

Client:

### TARGET PRICE

\$40,000,000

### GROSS REVENUE

25000000

### EBITDA

3000000

### BUSINESS TYPE

Fabrication, Fabrication, Pharmaceutique, Pharmaceutique

### ESTABLISHED

1989

### REASON FOR SELLING

Retraite

### COUNTRY

Inde

### BUSINESS ID

L#20210013

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction.

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

[www.mergerscorp.com](http://www.mergerscorp.com)



**MERGERSCORP**

The Leader In Business Sales Mergers & Acquisitions

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)